TARDIVE DYSKINESIA DRUGS MARKET ANALYSIS

Tardive dyskinesia (TD) is a form of dyskinesia that is difficult to treat. It is a nerve disorder characterized by involuntary movements such as jaw, lips, and tongue, considered as grimacing, sticking the tongue out, and lip smacking. Some other symptoms are an individual experiencing involuntary movement of the lower and upper extremities and also breathing choking. According to Center for Drug Evaluation and Research, tardive dyskinesia can lead to disability and can further stigmatize patients with mental illness. Tardive akathisia, a type of tardive dyskinesia, involves acute pain, inner tension, anxiety, and a compulsive drive to move the body. Tardive dyskinesia usually occurs in patients who are under prolong administration of antipsychotic drugs for any neurological disorder such as depression, psychosis, and certain drugs to treat gastrointestinal disorders. In spite of various studies conducted by pharmaceutical companies to know the exact treatment mechanism for tardive dyskinesia, only one drug developed by Neurocrine Biosciences that has received approval. Strong pipeline drugs for treatment of TD disorder are expected to propel growth of the tardive dyskinesia drugs market.

Increasing incidence of neurological disorders to drive growth the Tardive Dyskinesia Drugs Market

According to Mental Health America, the occurrence of tardive dyskinesia is estimated to be 10 to 20% of patients who are earlier treated with long term anti-psychotic medications. According to Neurocrine’s Chief Medical Officer, Chris O’Brien, all doctors and psychiatrists now accept Tardive dyskinesia as a prevalent condition. However, according to Neurocrine Bioscience, there are still an estimated 500,000 people in the U.S., who are affected by Tardive Dyskinesia each year. Lack of awareness on TD and its medication can hinder growth of global tardive dyskinesia drugs market.

Valbenazine to gain the major market share in TD Drugs Market globally

The global tardive dyskinesia drugs market is segmented on the basis of the sub-types, drugs, end user, and geography. On the basis of sub-type, the global market is divided into choreoathetosis, tardive dystonia, blepharospasm, and tardive akathisia. On the basis of drugs, the Global Market is divided into Valbenazine, Tetrabenazine, and others (deutetrabenazine and VMAT2 inhibitor). On the basis of end user, the global market is divided into hospitals, pharmacies, drug stores, and e-commerce.

Increased use of long-term neuroleptic drugs increases the risk of tardive dyskinesia, which proportionally boost the tardive dyskinesia drugs market

Regional segmentation in TD Drugs Market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest share in tardive dyskinesia drugs industry.  For instance, according to Virtual Medical Center, Australia, tardive dyskinesia is observed in around 15-30% of patients in the U.S. who have been prescribed with long-term neuroleptic drugs administration. Patients with mood disorders such as depression, anxiety disorders, and bipolar affective disorder are at greater risk of developing tardive dyskinesia as compared to people suffering from schizophrenia. The symptoms of tardive dyskinesia will remit within 3 months of stopping neuroleptic drugs for 1 in 3 patients with tardive dyskinesia. Thus, the increase in prevalence of mental disorders would boost the tardive dyskinesia drugs market growth.

Strong clinical trial pipeline to treat Tardive Dyskinesia is expected to boost the market for Tardive Dyskinesia Drugs Market in near future   

Key players operating in the tardive dyskinesia market include Valeant Pharmaceuticals, Neurocrine Biosciences, and Teva Pharmaceutical Industries. There are quite a few companies in Tardive Dyskinesia Market, which are striving hard to understand the mechanism to treat dyskinesia and are constantly working towards developing innovative drugs in order to provide accurate test results. Teva pharmaceutical is also conducting clinical trials of deutetrabenazine for tardive dyskinesia that were started by Auspex Pharmaceutical in 2015.

Key Developments

1. Major companies in the market are focused on various growth strategies such as gaining product approvals from regulatory authorities, in order expand their product portfolio. For instance, in April 2017, Neurocrine Biosciences, Inc., a biopharmaceutical company, received the U.S. Food and Drugs Administration approval for Ingrezza capsules, which are indicated for the treatment of adults suffering from tardive dyskinesia.
2. Key players in the market are involved in various business strategies such as gaining product approvals from regulatory authorities, in order to enhance their market presence. For instance, in August 2017, Teva Pharmaceutical Industries received the U.S. FDA approval for AUSTEDO tablets, which is indicated for the treatment of patients suffering from tardive dyskinesia.